Is rosiglitazone a promising treatment for ulcerative colitis?

Nature Clinical Practice Gastroenterology and Hepatology

Volumn 5, Issue 9, 2008, Pages 486-487

  Milestone, Andrew N ^a   Iacucci, Marietta ^a   Ghosh, Subrata ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; IMMUNOMODULATING AGENT; MESALAZINE; MITOGEN ACTIVATED PROTEIN KINASE P38; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PLACEBO; PREDNISOLONE; ROSIGLITAZONE; TRANSCRIPTION FACTOR RELA; TUMOR NECROSIS FACTOR ANTIBODY;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CYTOKINE RELEASE; DIABETES MELLITUS; DISEASE SEVERITY; DRUG EFFICACY; DRUG RESPONSE; DRUG TREATMENT FAILURE; EDEMA; FRACTURE; HEART FAILURE; HEART INFARCTION; HUMAN; INSULIN RESISTANCE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RANDOMIZED CONTROLLED TRIAL; REMISSION; RETINA MACULA EDEMA; TREATMENT DURATION; ULCERATIVE COLITIS; VISUAL IMPAIRMENT;

EID: 51349096816     PISSN: 17434378     EISSN: 17434386     Source Type: Journal    
DOI: 10.1038/ncpgasthep1226     Document Type: Article

References (12)

1. Nolte RT et al. (1998) Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor-gamma. Nature 395: 137-143
2. Marion R et al. (2008) Comparison of cytokine modulation by natural PPARγ ligands with synthetic ligands in intestinal-like Caco-2 cells - potential for dietary modulation of PPARγ in intestinal inflammation. Am J Clin Nutr 87: 939-948
3. Sanchez-Hidalgo M et al. (2005) Rosiglitazone, an agonist of peroxisome proliferator-activated receptor gamma, reduces chronic colonic inflammation in rats. Biochem Pharmacol 69: 1733-1744
4. Sanchez-Hildalgo M et al. (2007) Rosiglitazone. A PPARγ ligand, modulates signal transduction pathways during the development of acute TNBS-induced colitis in rats. Euro J Pharmacol 562: 247-258
5. Nencioni A et al. (2002) Dendritic cell immunogenicity is regulated by peroxisome proliferator-activated receptor gamma. J Immunol 169: 1228-1235
6. Narayanan BA et al. (2003) Modulation of inducible nitric oxide synthase and related proinflammatory genes by the omega-3 fatty acid docosahexaenoic acid in human colon cancer cells. Cancer Res 63 972-979
7. Dubuquoy L et al. (2003) Impaired expression of peroxisome proliferator-activated receptor gamma in ulcerative colitis. Gastroenterology 124: 1265-1276
8. Rousseaux C et al. (2005) Intestinal antiinflammatory effect of 5-aminosalicylic acid is dependent on peroxisome prol iferator-activated receptor-γ. J Exp Med 201: 1205-1215
9. Lewis JD et al. (2001) An open-label trial of the PPARγ ligand rosiglitazone for active ulcerative colitis. Am J Gastroenterol 96: 3323-3328
10. Lewis JD et al. (2008) Rosiglitazone for active ulcerative colitis: A randomised placebo-controlled trial. Gastroenterology 134: 688-695
11. Liang HL and Ouyang Q (2008) A clinical trial of combined use of rosiglitazone and 5-aminosalicylate for ulcerative colitis. World J Gastroenterol 14: 114-119
12. Singh S et al. (2007) Long-term risk of cardiovascular events with rosiglitazone: A meta-analysis. JAMA 298: 1189-1195